Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 25 | 2025 | 870 | 5.340 |
Why?
|
| Diabetes Mellitus, Type 2 | 16 | 2025 | 1415 | 3.670 |
Why?
|
| Autoantibodies | 9 | 2025 | 467 | 1.890 |
Why?
|
| C-Peptide | 6 | 2025 | 116 | 1.720 |
Why?
|
| Insulin-Secreting Cells | 4 | 2024 | 150 | 1.690 |
Why?
|
| Fabaceae | 1 | 2023 | 27 | 0.810 |
Why?
|
| Terminology as Topic | 1 | 2024 | 235 | 0.800 |
Why?
|
| Insulin | 5 | 2024 | 1258 | 0.770 |
Why?
|
| Acanthosis Nigricans | 1 | 2022 | 11 | 0.760 |
Why?
|
| Hyperglycemia | 2 | 2025 | 242 | 0.760 |
Why?
|
| Islets of Langerhans | 5 | 2024 | 178 | 0.750 |
Why?
|
| Child | 29 | 2025 | 25766 | 0.690 |
Why?
|
| Adolescent | 26 | 2025 | 20522 | 0.680 |
Why?
|
| Diabetic Ketoacidosis | 5 | 2025 | 169 | 0.660 |
Why?
|
| Diagnostic Errors | 1 | 2024 | 347 | 0.650 |
Why?
|
| Prescription Drugs | 1 | 2020 | 58 | 0.620 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2025 | 3479 | 0.610 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2018 | 13 | 0.600 |
Why?
|
| Genital Diseases, Male | 1 | 2018 | 12 | 0.600 |
Why?
|
| Kallmann Syndrome | 1 | 2018 | 13 | 0.600 |
Why?
|
| Penis | 1 | 2018 | 102 | 0.560 |
Why?
|
| Genetic Heterogeneity | 1 | 2018 | 141 | 0.540 |
Why?
|
| Autoimmunity | 1 | 2018 | 181 | 0.540 |
Why?
|
| Nomograms | 1 | 2017 | 38 | 0.540 |
Why?
|
| Humans | 47 | 2025 | 133717 | 0.540 |
Why?
|
| Parathyroid Neoplasms | 1 | 2017 | 23 | 0.530 |
Why?
|
| Hypercalcemia | 1 | 2017 | 42 | 0.530 |
Why?
|
| Hypothalamic Diseases | 1 | 2017 | 38 | 0.530 |
Why?
|
| Failure to Thrive | 1 | 2017 | 93 | 0.530 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 285 | 0.530 |
Why?
|
| Phosphates | 1 | 2017 | 120 | 0.530 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2017 | 33 | 0.520 |
Why?
|
| Astrocytoma | 1 | 2017 | 113 | 0.510 |
Why?
|
| Adenoma | 1 | 2017 | 143 | 0.480 |
Why?
|
| Autoimmune Diseases | 1 | 2017 | 277 | 0.460 |
Why?
|
| Insulin Resistance | 4 | 2024 | 696 | 0.420 |
Why?
|
| Kidney | 2 | 2017 | 1418 | 0.400 |
Why?
|
| Male | 25 | 2025 | 65858 | 0.400 |
Why?
|
| Kidney Diseases | 1 | 2017 | 505 | 0.380 |
Why?
|
| Chromosome Deletion | 1 | 2015 | 664 | 0.370 |
Why?
|
| Female | 22 | 2025 | 71608 | 0.320 |
Why?
|
| Infant | 9 | 2024 | 13174 | 0.260 |
Why?
|
| Genetic Testing | 2 | 2024 | 1094 | 0.250 |
Why?
|
| Genetic Variation | 2 | 2024 | 1621 | 0.240 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2025 | 2936 | 0.240 |
Why?
|
| Probability | 1 | 2025 | 335 | 0.230 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2024 | 18 | 0.220 |
Why?
|
| Prediabetic State | 1 | 2024 | 63 | 0.220 |
Why?
|
| HLA Antigens | 1 | 2025 | 253 | 0.210 |
Why?
|
| Young Adult | 6 | 2025 | 9873 | 0.210 |
Why?
|
| Racemethionine | 1 | 2023 | 6 | 0.210 |
Why?
|
| Insulin, Regular, Human | 1 | 2023 | 12 | 0.210 |
Why?
|
| Adult | 11 | 2025 | 31876 | 0.210 |
Why?
|
| Family | 2 | 2025 | 589 | 0.210 |
Why?
|
| Prospective Studies | 3 | 2024 | 6589 | 0.210 |
Why?
|
| Prognosis | 5 | 2024 | 5073 | 0.210 |
Why?
|
| Retrospective Studies | 8 | 2025 | 17421 | 0.210 |
Why?
|
| Leptin | 2 | 2023 | 224 | 0.200 |
Why?
|
| Methionine | 1 | 2023 | 105 | 0.200 |
Why?
|
| Amino Acids | 1 | 2025 | 687 | 0.200 |
Why?
|
| Citrulline | 1 | 2023 | 114 | 0.190 |
Why?
|
| Glutamine | 1 | 2023 | 222 | 0.190 |
Why?
|
| Breast Neoplasms | 2 | 2012 | 2767 | 0.180 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2023 | 262 | 0.180 |
Why?
|
| Metformin | 1 | 2023 | 165 | 0.180 |
Why?
|
| Child, Preschool | 8 | 2024 | 14806 | 0.180 |
Why?
|
| Body Weight | 1 | 2025 | 1037 | 0.180 |
Why?
|
| Ataxia | 1 | 2022 | 177 | 0.180 |
Why?
|
| Puberty | 1 | 2021 | 104 | 0.170 |
Why?
|
| Arginine | 1 | 2023 | 350 | 0.170 |
Why?
|
| Biomarkers | 3 | 2025 | 3430 | 0.170 |
Why?
|
| Frameshift Mutation | 1 | 2021 | 199 | 0.170 |
Why?
|
| Prevalence | 2 | 2024 | 2667 | 0.170 |
Why?
|
| Precision Medicine | 1 | 2023 | 355 | 0.170 |
Why?
|
| Tachycardia, Ventricular | 1 | 2022 | 207 | 0.160 |
Why?
|
| Diagnosis, Differential | 2 | 2025 | 1974 | 0.160 |
Why?
|
| Minority Groups | 2 | 2018 | 255 | 0.160 |
Why?
|
| Pilot Projects | 1 | 2023 | 1487 | 0.150 |
Why?
|
| Hypoglycemic Agents | 2 | 2023 | 489 | 0.150 |
Why?
|
| Pedigree | 1 | 2021 | 1695 | 0.140 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 959 | 0.140 |
Why?
|
| Anthropometry | 1 | 2018 | 205 | 0.140 |
Why?
|
| Heart Arrest | 1 | 2022 | 376 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2022 | 791 | 0.140 |
Why?
|
| Electronic Health Records | 1 | 2024 | 797 | 0.140 |
Why?
|
| Seizures | 1 | 2022 | 889 | 0.140 |
Why?
|
| Cystography | 1 | 2017 | 2 | 0.140 |
Why?
|
| Cardiomyopathies | 1 | 2022 | 516 | 0.140 |
Why?
|
| Drug Therapy | 1 | 2017 | 93 | 0.130 |
Why?
|
| Mutation, Missense | 1 | 2021 | 931 | 0.130 |
Why?
|
| Parathyroidectomy | 1 | 2017 | 48 | 0.130 |
Why?
|
| Incidental Findings | 1 | 2017 | 129 | 0.120 |
Why?
|
| Fluid Therapy | 1 | 2017 | 149 | 0.120 |
Why?
|
| Risk Assessment | 1 | 2025 | 3711 | 0.120 |
Why?
|
| Ambulatory Care Facilities | 1 | 2017 | 239 | 0.120 |
Why?
|
| Disease Progression | 2 | 2020 | 2239 | 0.120 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 936 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2015 | 71 | 0.120 |
Why?
|
| Mullerian Ducts | 1 | 2015 | 42 | 0.120 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 1199 | 0.110 |
Why?
|
| Intellectual Disability | 1 | 2022 | 1078 | 0.110 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2015 | 43 | 0.110 |
Why?
|
| Glomerular Filtration Rate | 1 | 2017 | 549 | 0.110 |
Why?
|
| Risk Factors | 2 | 2025 | 11112 | 0.100 |
Why?
|
| Testosterone | 1 | 2018 | 618 | 0.100 |
Why?
|
| Ultrasonography | 1 | 2017 | 1004 | 0.090 |
Why?
|
| Cross-Sectional Studies | 4 | 2023 | 3743 | 0.090 |
Why?
|
| Blood Glucose | 2 | 2025 | 1194 | 0.090 |
Why?
|
| Stents | 1 | 2017 | 877 | 0.080 |
Why?
|
| Registries | 1 | 2017 | 1571 | 0.080 |
Why?
|
| Consensus | 2 | 2024 | 738 | 0.080 |
Why?
|
| Obesity | 2 | 2020 | 2431 | 0.080 |
Why?
|
| United States | 1 | 2025 | 11709 | 0.080 |
Why?
|
| Mutation | 1 | 2022 | 6294 | 0.070 |
Why?
|
| Age of Onset | 2 | 2020 | 636 | 0.070 |
Why?
|
| Middle Aged | 4 | 2025 | 29296 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 3843 | 0.060 |
Why?
|
| Body Mass Index | 2 | 2023 | 1713 | 0.060 |
Why?
|
| Overweight | 2 | 2020 | 385 | 0.060 |
Why?
|
| Age Factors | 2 | 2024 | 2989 | 0.060 |
Why?
|
| Infant, Newborn | 1 | 2018 | 8589 | 0.060 |
Why?
|
| Glucose Tolerance Test | 1 | 2025 | 226 | 0.060 |
Why?
|
| Pediatric Obesity | 2 | 2021 | 408 | 0.050 |
Why?
|
| Verapamil | 1 | 2022 | 58 | 0.050 |
Why?
|
| Isoproterenol | 1 | 2022 | 109 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2023 | 440 | 0.050 |
Why?
|
| Magnesium | 1 | 2022 | 127 | 0.050 |
Why?
|
| Metabolomics | 1 | 2025 | 456 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2017 | 13003 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2025 | 847 | 0.040 |
Why?
|
| Germ Cells | 1 | 2022 | 203 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2025 | 1154 | 0.040 |
Why?
|
| Sex Factors | 1 | 2024 | 1385 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2025 | 1213 | 0.040 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2022 | 227 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 554 | 0.040 |
Why?
|
| Prenatal Care | 1 | 2022 | 359 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2022 | 369 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2023 | 682 | 0.040 |
Why?
|
| Syndrome | 1 | 2022 | 1159 | 0.040 |
Why?
|
| Adiposity | 1 | 2020 | 206 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2020 | 335 | 0.040 |
Why?
|
| Dyslipidemias | 1 | 2021 | 244 | 0.040 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2022 | 477 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2025 | 3649 | 0.040 |
Why?
|
| Hypoglycemia | 1 | 2018 | 193 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2024 | 5468 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 920 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 3991 | 0.030 |
Why?
|
| Aged | 1 | 2012 | 21679 | 0.030 |
Why?
|
| Phenotype | 1 | 2022 | 4551 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2022 | 2713 | 0.020 |
Why?
|
| Pregnancy | 1 | 2022 | 7533 | 0.020 |
Why?
|
| Turkey | 1 | 2009 | 64 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 5194 | 0.020 |
Why?
|